drugset
drugset / Trial / NCT00903760

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

NCT00903760 ↗

Phase 2 Completed 42 enrolled M.D. Anderson Cancer Center Genzyme, a Sanofi Company · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if sequential administration of decitabine and clofarabine can help to control MDS better than decitabine alone. The safety of this drug combination will also be studied.

Timeline

Start
2010-01
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 10 mg/m2 Intravenous
Subject Decitabine Small molecule 20 mg/m2 Intravenous

Indications

myelodysplastic syndrome